SCHEMBL6074384

SCHEMBL6074384

CS(=O)(=O)Nc1ccc([C@@H](O)CN)cc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRB3 P13945 4/20 0.65
LMNA P02545 4/20 0.65
KDM4E B2RXH2 4/20 0.65
ADRB2 P07550 3/20 0.65
ADRB1 P08588 3/20 0.65
MEN1 O00255 1/20 0.65
KMT2A Q03164 1/20 0.65
GLA P06280 1/20 0.63
BLM P54132 1/20 0.63
ADRA2C P18825 2/20 0.61
ADRA1A P35348 1/20 0.61
ADRA1B P35368 1/20 0.61
CACNA1F O60840 1/20 0.52
CHRM2 P08172 1/20 0.52
ADRA2B P18089 1/20 0.52
CHRM3 P20309 1/20 0.52
HTR2A P28223 1/20 0.52
SLC6A4 P31645 1/20 0.52
DRD3 P35462 1/20 0.52
CACNA1D Q01668 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7243938 1.00 ADRB3 (0.65) ADRB3LMNAKDM4EADRB2ADRB1
SCHEMBL9445125 1.00 ADRB3 (0.65) ADRB3LMNAKDM4EADRB2ADRB1
SCHEMBL7244119 0.87 ADRB3 (0.61) ADRB3LMNAKDM4EADRB2ADRB1
Hydrochloric Acid SCHEMBL9134531 0.83 HPGD (0.50) ADRB3LMNAKDM4EADRB2ADRB1
SCHEMBL9447441 0.83 LMNA (0.65) ADRB3LMNAKDM4EADRB2ADRB1
SCHEMBL6075074 0.83 LMNA (0.65) ADRB3LMNAKDM4EADRB2ADRB1
SCHEMBL6499356 0.83 LMNA (0.65) ADRB3LMNAKDM4EADRB2ADRB1
SCHEMBL6074523 0.83 LMNA (0.65) ADRB3LMNAKDM4EADRB2ADRB1
SCHEMBL11420225 0.82 ADRB3 (0.61) ADRB3LMNAKDM4EADRB2ADRB1
SCHEMBL9688351 0.81 ADRB2 (0.72) ADRB3LMNAKDM4EADRB2ADRB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7022716-B2 Cyclic amine phenyl beta-3 adrenergic receptor agonists WYETH (US) 2006-04-04 US disclosed
US-20030144326-A1 Cyclic amine phenyl beta-3 adrenergic receptor agonists WYETH 2003-07-31 US disclosed
US-6525202-B2 E.g., substituted (4-amino-5-hydroxyphenyl)-oxy-)piperidinyl thiazolidin-2,4-dione; antidiabetic agents; atherosclerosis, gastrointestinal, metabolic disorders, glaucoma, neurogenetic inflammation, ocular hypertension and frequent urination WYETH 2003-02-25 US disclosed
US-20020028835-A1 Cyclic amine phenyl beta-3 adrenergic receptor agonists WYETH 2002-03-07 US disclosed
EP-0338793-B1 Anti-hypertensive sulfonanilides WELLCOME FOUND (GB) 1993-10-27 EP disclosed
US-5194450-A Hypotensive agents BURROUGHS WELLCOME CO. (US) 1993-03-16 US disclosed
US-5102914-A Racemic mixtures BURROUGHS WELLCOME CO. (US) 1992-04-07 US disclosed
EP-0338793-A2 Anti-hypertensive sulfonanilides THE WELLCOME FOUNDATION LIMITED (GB) 1989-10-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030144326-A1 Cyclic amine phenyl beta-3 adrenergic receptor agonists ADRB1, ADRB3, ADRB2 ADRB3 2/4885LMNA 2593/4885KDM4E 4266/4885
US-20020028835-A1 Cyclic amine phenyl beta-3 adrenergic receptor agonists ADRB1, ADRB3, ADRB2 ADRB3 2/4885LMNA 2593/4885KDM4E 4266/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.